People with relapsing-remitting and active secondary-progressive multiple sclerosis (MS), as well as those with clinically isolated syndrome (CIS, an initial neurological episode), have a new ...
The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results